Patents Assigned to Celon Pharma S.A.
-
Patent number: 11964938Abstract: A compound of the formula (I) wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom, and * denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes.Type: GrantFiled: January 7, 2019Date of Patent: April 23, 2024Assignee: CELON PHARMA S.A.Inventors: Mateusz Mach, Radoslaw Dzida, Damian Smuga, Filip Stelmach, Mikolaj Matloka, Katarzyna Bazydlo, Krzysztof Dubiel, Maciej Wieczorek, Jerzy Pieczykolan
-
Patent number: 11925607Abstract: An inhalable pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression by administration via pulmonary route, treatment comprising cycle of multiple sequences of administration by inhalation, said cycle lasting from 10 days to 30 days, wherein each of multiple sequences of administration is performed in a one single day, with 2 to 4 days intervals between sequences, and each of said sequences consists of multiple single dose inhalations separated by a break period lasting at least 5 minutes. The composition is especially useful for the treatment of treatment-resistant depression.Type: GrantFiled: September 24, 2019Date of Patent: March 12, 2024Assignee: CELON PHARMA S.A.Inventors: Maciej Wieczorek, Sylwia Janowska
-
Patent number: 11072619Abstract: A compound or its acid addition salt of the general formula (I), wherein R1 represents phenyl substituted with one or two substituents selected from the group consisting of halogen and C1-C3 alkoxyl, or 6-membered heteroaryl with 1 or 2 nitrogen atoms, which is unsubstituted or substituted with a substituent selected from the group consisting of —NH2, halogen, alkyl C1-C4, alkoxyl C1-C3, and 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from the group consisting of N and O. The compound has the activity of kinase JAK1/JAK3 inhibitor and can find use in the treatment of chronic inflammatory and autoimmunological diseases.Type: GrantFiled: May 10, 2018Date of Patent: July 27, 2021Assignee: Celon Pharma S.A.Inventors: Michal Mroczkiewicz, Bartosz Stypik, Anna Bujak, Krzysztof Szymczak, Pawel Gunerka, Krzysztof Dubiel, Maciej Wieczorek, Jerzy Pieczykolan
-
Publication number: 20200399198Abstract: A compound of the formula (I) wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom, and * denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes.Type: ApplicationFiled: January 7, 2019Publication date: December 24, 2020Applicant: CELON PHARMA S.A.Inventors: Mateusz MACH, Radoslaw DZIDA, Damian SMUGA, Filip STELMACH, Mikolaj MATLOKA, Katarzyna BAZYDLO, Krzysztof DUBIEL, Maciej WIECZOREK, Jerzy PIECZYKOLAN
-
Publication number: 20200337999Abstract: A dry powder inhalable pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression by administration via pulmonary route. The composition is especially useful for the treatment of treatment-resistant or treatment-refractory depression.Type: ApplicationFiled: September 28, 2018Publication date: October 29, 2020Applicant: CELON PHARMA S.A.Inventors: Maciej WIECZOREK, Ewa TRATKIEWICZ, Przemyslaw PERKO
-
Publication number: 20200199128Abstract: A compound or its acid addition salt of the general formula (I), wherein R1 represents phenyl substituted with one or two substituents selected from the group consisting of halogen and C1-C3 alkoxyl, or 6-membered heteroaryl with 1 or 2 nitrogen atoms, which is unsubstituted or substituted with a substituent selected from the group consisting of —NH2, halogen, alkyl C1-C4, alkoxyl C1-C3, and 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from the group consisting of N and O. The compound has the activity of kinase JAK1/JAK3 inhibitor and can find use in the treatment of chronic inflammatory and autoimmunological diseases.Type: ApplicationFiled: May 10, 2018Publication date: June 25, 2020Applicant: CELON PHARMA S.A.Inventors: Michal MROCZKIEWICZ, Bartosz STYPIK, Anna BUJAK, Krzysztof SZYMCZAK, Pawel GUNERKA, Krzysztof DUBIEL, Maciej WIECZOREK, Jerzy PIECZYKOLAN
-
Patent number: 10138247Abstract: A compound of the general formula (I) wherein Y represents —CH2— or >C=0; R1 is selected from the group consisting of A1, A2 and A3; R2 represents dioxothiomorpholino moiety B1, piperazinyl moiety B2, azetidinyl moiety B3, or piperidinyl moiety B4; R3 is selected from the group consisting of H, halogen, and C1-C4 alkyl; R4 is selected from the group consisting of C1-C4 alkyl, C3-C4-cycloalkyl, C1-C4 alkyl substituted with C1-C4 alkoxy, and CHF2, and their pharmaceutically acceptable salts. Pharmaceutical compositions comprising said compounds and their use in the treatment of diseases of immune system, inflammatory diseases and cancer.Type: GrantFiled: March 30, 2016Date of Patent: November 27, 2018Assignee: CELON PHARMA, S.A.Inventors: Barbara Dymek, Marcin Zagozda, Maciej Wieczorek, Krzysztof Dubiel, Aleksandra Stanczak, Daria Zdzalik, Pawel Gunerka, Mariola Sekular, Maciej Dziachan
-
Patent number: 10138245Abstract: Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents —C(CH3), A represents unsubstituted or substituted 5-, 6- or 10-membered aryl or heteroaryl, n is 0 or 1 and B is a bicyclic heteromoiety defined in the specification. Compounds are phosphodiesterase 10A inhibitors and can find use in medicine in the treatment psychotic, neurological and cognitive functions diseases and disorders.Type: GrantFiled: May 14, 2015Date of Patent: November 27, 2018Assignee: CELON PHARMA S.A.Inventors: Rafal Moszczynski-Petkowski, Lukasz Bojarski, Maciej Wieczorek, Jakub Majer, Sylwia Janowska, Mikolaj Matloka, Malgorzata Borkowska, Filip Stefaniak, Monika Lamparska-Przybysz, Krzysztof Dubiel
-
Patent number: 9776988Abstract: A compound represented by the general Formula (I), wherein hydrogen atoms shown as attached to pyrazole and benzimidazole rings are attached to one of nitrogen atoms of the pyrazole or benzimidazole ring, respectively; R1 represents —X-Q-P, wherein X is absent or represents —CH2—, —C(O)—, or —C(O)NH—(CH2)k—, wherein k is 0, 1 or 2; Q is selected from the group consisting of Q1, Q2, Q3, Q4 and Q5; P is absent or represents straight- or branched-chain C1-C3 alkyl, —(CH2)l—NR2R3, or —(CH2)m—C(O)—NR2R3, wherein l and m independently of each other represent 0, 1 or 2, with the proviso that when B in Q1 represents oxygen atom, then P is absent; and R2 and R3 independently represent C1 or C2 alkyl, or R2 and R3 together with nitrogen atom to which they are both attached form a 6-membered saturated heterocyclic ring, wherein one of carbon atoms can be replaced with oxygen, —NH— or —N(C1-C2)alkyl-; and acid addition salts thereof. The compound can be useful in the treatment of cancer diseases.Type: GrantFiled: March 7, 2014Date of Patent: October 3, 2017Assignee: Celon Pharma S.A.Inventors: Daria Zdzalik, Joanna Lipner, Maciej Wieczorek, Karolina Dzwonek, Abdellah Yamani, Krzysztof Dubiel, Monika Lamparska-Przybysz, Paulina Grygielewicz, Aleksandra Stanczak
-
Publication number: 20170114064Abstract: Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents —C(CH3), A represents unsubstituted or substituted 5-, 6- or 10-membered aryl or heteroaryl, n is 0 or 1 and B is a bicyclic heteromoiety defined in the specification. Compounds are phosphodiesterase 10A inhibitors and can find use in medicine in the treatment psychotic, neurological and cognitive functions diseases and disorders.Type: ApplicationFiled: May 14, 2015Publication date: April 27, 2017Applicant: Celon Pharma S.A.Inventors: Rafal MOSZCZYNSKI-PETKOWSKI, Lukasz BOJARSKI, Maciej WIECZOREK, Jakub MAJER, Sylwia JANOWSKA, Mikolaj MATLOKA, Malgorzata BORKOWSKA, Filip STEFANIAK, Monika LAMPARSKA-PRZYBYSZ, Krzysztof DUBIEL
-
Publication number: 20160039794Abstract: A compound represented by the general Formula (I), wherein hydrogen atoms shown as attached to pyrazole and benzimidazole rings are attached to one of nitrogen atoms of the pyrazole or benzimidazole ring, respectively; R1 represents —X-Q-P, wherein X is absent or represents —CH2—, —C(O)—, or —C(O)NH—(CH2)k—, wherein k is 0, 1 or 2; Q is selected from the group consisting of Q1, Q2, Q3, Q4 and Q5; P is absent or represents straight- or branched-chain C1-C3 alkyl, —(CH2)l—NR2R3, or —(CH2)m—C(O)—NR2R3, wherein l and m independently of each other represent 0, 1 or 2, with the proviso that when B in Q1 represents oxygen atom, then P is absent; and R2 and R3 independently represent C1 or C2 alkyl, or R2 and R3 together with nitrogen atom to which they are both attached form a 6-membered saturated heterocyclic ring, wherein one of carbon atoms can be replaced with oxygen, —NH—or —N(C1-C2)alkyl-; and acid addition salts thereof. The compound can be useful in the treatment of cancer diseases.Type: ApplicationFiled: March 7, 2014Publication date: February 11, 2016Applicant: CELON PHARMA S.A.Inventors: Daria ZDZALIK, Joanna LIPNER, Maciej WIECZOREK, Karolina DZWONEK, Abdellah YAMANI, Krzysztof DUBIEL, Monika LAMPARSKA-PRZYBYSZ, Paulina GRYGIELEWICZ, Aleksandra STANCZAK
-
Patent number: D737425Type: GrantFiled: January 3, 2014Date of Patent: August 25, 2015Assignee: Celon Pharma S.A.Inventor: Maciej Wieczorek
-
Patent number: D746378Type: GrantFiled: January 28, 2014Date of Patent: December 29, 2015Assignee: Celon Pharma S.A.Inventors: Bogdan Szczepan Manowski, Maciej Wieczorek
-
Patent number: D759163Type: GrantFiled: January 28, 2014Date of Patent: June 14, 2016Assignee: Celon Pharma S.A.Inventors: Bogdan Szczepan Manowski, Maciej Wieczorek